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Somatic genetic abnormalities are key initiators and drivers of disease in acute lymphoblastic 
leukaemia (ALL). Several chromosomal abnormalities have proven clinical utility as prognostic and 
predictive biomarkers at initial diagnosis. However, the role of genetic biomarkers in relapsed ALL is 
less well understood and has rarely been studied comprehensively within a clinical trial.  
We evaluated the role of genetics in predicting outcome among children with relapsed B-cell 
precursor ALL treated on the international trial, ALLR3. 
We analysed cytogenetic, copy number alteration (CNA) and sequence mutation data at relapse in 
representative cohorts of patients. Patients with a very early relapse (<18 months from first 
diagnosis) and those patients with an isolated marrow relapse who had an early relapse (<6 months 
from stopping frontline therapy) were treated as clinical high risk (HR) whereas all other patients 
were treated as clinical standard risk (SR).  
Clinical HR patients accounted for 25% of the cohort and had a significantly inferior overall survival 
(OS) compared to SR patients: 25% (95% CI 15-37) v 65% (57-72), p<0.0001. A total of 427 patients 
were assigned to pre-defined cytogenetic risk groups which were predictive of survival post-relapse 
in both univariate and multivariate analysis adjusting for clinical risk: good risk (GR) cytogenetics 
(ETV6-RUNX1, high hyperdiploidy) 5 years OS 68% (60-75); intermediate risk (IR) cytogenetics (TCF3-
PBX1, IGH translocations, B-other ALL) 47% (38-55); and HR cytogenetics (BCR-ABL1, MLL 
translocations, near haploidy, low hypodiploidy, iAMP21, TCF3-HLF) 26% (14-40), p<0.001. However, 
the prognostic effect of cytogenetic risk group was strongest within the clinical SR group. A 
representative cohort of 240 patients with marrow involvement was screened for CNA and 
mutations affecting key genes in ALL. Over 75% patients harboured at least one CNA or mutation: 
CDKN2A/B (39%), IKZF1 (22%), PAX5 (20%), TP53 (17%), ETV6 (16%), KRAS (12%), NRAS (12%), NR3C1 
(9%), PAR1 (8%), PTPN11 (8%), RB1 (4%), EBF1 (4%), BTG1 (4%), FLT3 (4%), CBL (1%). Cox models 
adjusted for clinical risk revealed that only four genes were associated with outcome. Patients with a 
TP53 alteration or a deletion of either NR3C1 or  BTG1 had an inferior progression free survival (PFS) 
with hazard ratios of 2.07 (95% CI 1.20-3.58), p=0.009 and 2.26 (1.38-3.70), p=0.001, respectively. In 
addition, cytogenetic GR patients with a NRAS mutation had an inferior PFS compared with other GR 
cytogenetic patients 2.54 (1.24-5.22), p=0.01. The integration of clinical and cytogenetic risk groups 
with TP53, NR3C1, BTG1 and NRAS gene status revealed three groups: (1) Favourable - clinical SR 
patients with GR cytogenetics and without a TP53, NR3C1, BTG1 or NRAS abnormality; (2) 
Intermediate - clinical SR patients with GR cytogenetics and a TP53, NR3C1, BTG1 or NRAS 
abnormality plus clinical SR patients with IR cytogenetics; and (3) Adverse - all clinical and 
cytogenetic HR patients. The three groups accounted for 35%, 35% and 30% patients, respectively, 
and had markedly distinct OS rates: 78% (61-89), 56% (46-65) and 27% (19-35), p<0.001, 
respectively. Multivariate Cox models including variables for treatment and minimal residual disease 
did not materially alter the results. Receiver operating characteristic (ROC) curve analysis revealed 
that the new index had significantly greater predictive power than clinical risk alone for both PFS and 
OS: area under the curve = 0.73 v 0.67, p=0.02 and 0.75 v 0.69, p=0.03, respectively. In conclusion, 
we have integrated key genetic information with clinical risk to improve risk prediction in relapsed 
ALL and propose a three-tier index which could be used to develop risk-directed therapy.  
